Erection is basically a spinal reflex that can be initiated by recruitment of penile afferents,
both autonomic and somatic, and supraspinal influences from visual, olfactory, and …

Introduction Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction
worldwide. ED is a chronic condition that exerts a negative impact on male self-esteem and …

Early prediction of clearance mechanisms allows for the rapid progression of drug discovery
and development programs, and facilitates risk assessment of the pharmacokinetic …

Cyclic GMP–phosphodiesterase type 5 (PDE5) inhibition has been shown to counteract
maladaptive cardiac changes triggered by diabetes in some but not all studies. We …

Phosphodiesterases (PDEs) consisted of 11 subtypes (PDE1 to PDE11) and over 40
isoforms that regulate levels of cyclic guanosine monophosphate (cGMP) and cyclic …

Differences in clinical pharmacology of the currently marketed phosphodiesterase (PDE) 5
inhibitors sildenafil, vardenafil and tadalafil are largely determined by their pharmacokinetic …

ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors ameliorate low urinary
tract (LUT) symptoms in men with ED and symptomatic benign prostatic hyperplasia (BPH) …

Introduction: Erectile dysfunction (ED) is a highly prevalent condition affecting nearly one in
five men worldwide. The advent of phosphodiesterase type 5 inhibitors (PDE5i) has …

The treatment for erectile dysfunction (ED) was revolutionized with the development of
phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil (Cialis®; Eli Lilly and Company …

United States in 2006. Erectile dysfunction (ED) currently affects 30 million men in the United
States and 150 million men worldwide and will become more prevalent as the population …